Brief: Skye Bioscience reports early trial data for Cbeyond combo and solo use of Nimacimab
06/10/2025 12:08
Oct 6 (Reuters) - Skye Bioscience Inc SKYE.O: SKYE BIOSCIENCE REPORTS TOPLINE CBEYOND™ PHASE 2A DATA FROM NIMACIMAB MONOTHERAPY AND COMBINATION CLINICAL TRIAL SKYE BIOSCIENCE INC - NIMACIMAB MONOTHERAPY FAILS TO MEET PRIMARY WEIGHT LOSS ENDPOINT SKYE BIOSCIENCE INC - ADDITIONAL WEIGHT LOSS WITH NIMACIMAB AND SEMAGLUTIDE COMBINATION SKYE BIOSCIENCE INC - NIMACIMAB ALONE & IN COMBINATION SHOWS CLEAN SAFETY PROFILE IN TRIAL SKYE BIOSCIENCE INC - EXPECTS TO REPORT DATA FROM EXTENSION STUDY IN Q1 2026 Source text: ID:nGNX9XTdFZ Further company coverage: SKYE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Skye Bioscience
See all newsBrief: Skye Announces Cohort Review Committee Approved Opening Of Cohort 2 Based On Favorable Safety Data From First Four Participants Treated In Cohort 1
U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis
U.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
U.S. STOCKS ON THE MOVE-Energy firms, Estee Lauder, HMH Holding
Skye Bioscience rises as it begins testing higher doses of obesity drug